Aadi Bioscience Inc
NASDAQ:AADI

Watchlist Manager
Aadi Bioscience Inc Logo
Aadi Bioscience Inc
NASDAQ:AADI
Watchlist
Price: 2.02 USD -1.46% Market Closed
Market Cap: 49.9m USD

During the last 3 months Aadi Bioscience Inc insiders have not bought any shares, and have not sold any shares.

The last transaction was made on Mar 3, 2025 by Ball Bryan , who sold 5k USD worth of AADI shares.

Last Transactions:
Giacobello Scott M.
$-6.6k
Ball Bryan
$-5k
Lennon David James
$-13.4k
Lennon David James
$-18.8k
Desai Neil
$-68.3k
Desai Neil
$-7.6k
Desai Neil
$-26.7k
Desai Neil
$-23.1k
Desai Neil
$-11.6k
Desai Neil
$-45.6k
Desai Neil
$-35.7k
Desai Neil
$-35.8k
Desai Neil
$-77.2k
Desai Neil
$-49.5k
Desai Neil
$-41.1k
Desai Neil
$-31.4k
Desai Neil
$-53.2k
Desai Neil
$-73.3k
Desai Neil
$-86.5k
Desai Neil
$-33.9k
Desai Neil
$-78.9k
Desai Neil
$-56k
Desai Neil
$-42.9k
Desai Neil
$-141.1k
Desai Neil
$-44.6k
Desai Neil
$-67.3k
Desai Neil
$-111.7k
Desai Neil
$-37.6k
Desai Neil
$-118.3k
Desai Neil
$-82.9k
Desai Neil
$-100.3k
Desai Neil
$-118.5k
View All Transactions

During the last 3 months Aadi Bioscience Inc insiders have not bought any shares, and have not sold any shares.

The last transaction was made on Mar 3, 2025 by Ball Bryan , who sold 5k USD worth of AADI shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
25k USD
3
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
0
0 USD

Aadi Bioscience Inc
Insider Trading Chart

Aadi Bioscience Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Aadi Bioscience Inc
Last Insider Transactions

Global
Insiders Monitor

Aadi Bioscience Inc
Glance View

Market Cap
49.7m USD
Industry
Biotechnology

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Pacific Palisades, California and currently employs 39 full-time employees. The company went IPO on 2018-06-26. The Company’s primary focus is to bring transformational therapies to cancer patients with mechanistic target of rapamycin (mTOR) pathway driver alterations such as alterations in TSC1 or TSC2 genes. The Company’s initial focus is the treatment of an ultra-rare cancer perivascular epithelioid cell tumor (PEComa). The Company’s lead product, FYARROTM, is an mTOR inhibitor bound to human albumin that has tumor accumulation, mTOR target suppression, and tumor growth inhibition over other mTOR inhibitors in preclinical models. FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with advanced unresectable or metastatic perivascular epithelioid cell tumor (PEComa).

AADI Intrinsic Value
2.07 USD
Undervaluation 2%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top